Mammary Cell News Volume 4.18 | May 10 2012

LABORATORY RESEARCH

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Scientists examined whether the anti-tumor effects of radiotherapy in established triple-negative breast tumors could be enhanced with combinations of clinically relevant monoclonal antibodies, designed to stimulate immunity or relieve immunosuppression. [Cancer Res] Abstract

Targeted Silencing of the Oncogenic Transcription Factor SOX2 in Breast Cancer
Researchers demonstrated the effectiveness and therapeutic potential of engineered artificial transcription factors (ATF) to mediate potent and long-lasting down-regulation of oncogenic TF expression in cancer cells. [Nucleic Acids Res] Full Article

Interaction with Suv39H1 Is Critical for Snail-Mediated E-Cadherin Repression in Breast Cancer
Scientists found knockdown of Suv39H1 (suppressor of variegation 3-9 homolog 1) restored E-cadherin expression by blocking H3K9me3 and DNA methylation, and resulted in the inhibition of cell migration, invasion and metastasis of basal-like breast cancer. [Oncogene] Abstract

Met Signaling Regulates Growth, Repopulating Potential and Basal Cell-Fate Commitment of Mammary Luminal Progenitors: Implications for Basal-Like Breast Cancer
Results emphasize a critical role for Met in promoting deregulated proliferation and basal plasticity of normal luminal progenitors in the mammary gland, a complex of events that may be required for sustaining the functional and phenotypic properties of basal-like breast tumors. [Oncogene] Abstract

Crk Adaptor Proteins Act as Key Signaling Integrators for Breast Tumorigenesis
Investigators highlighted the physiological importance of CT10 regulator of kinase (Crk) proteins in regulating growth of aggressive basal breast cancer cells, and identified Crk-dependent signaling networks as promising therapeutic targets. [Breast Cancer Res] Full Article

Cyclin E2 Overexpression Is Associated with Endocrine Resistance but Not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Researchers examined the role of cyclin E2 in antiestrogen resistance in vitro and its potential for therapeutic targeting through cyclin-dependent kinase (CDK) inhibition. [Mol Cancer Ther] Abstract

Arsenic Induces Functional Re-Expression of Estrogen Receptor α by Demethylation of DNA in Estrogen Receptor-Negative Human Breast Cancer
Researchers showed arsenic trioxide exhibits a previously undefined function, which induces re-expression estrogen receptor α (ERα) in ER-negative breast cancer cells through demethylation of the ERα promoter. [PLoS One] Full Article

Intracellular Mechanics and Activity of Breast Cancer Cells Correlate with Metastatic Potential
Scientists performed a comparative study using particle-tracking to evaluate the intracellular mechanics of living epithelial breast cells with varying invasiveness. [Cell Biochem Biophys] Abstract

CLINICAL RESEARCH

Randomized Phase II Trial of Everolimus in Combination with Tamoxifen in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors: A GINECO Study
Scientists evaluated the efficacy and safety of everolimus in combination with tamoxifen in patients with metastatic breast cancer resistant to aromatase inhibitors. [J Clin Oncol] Full Article

Weekly Paclitaxel Plus Trastuzumab in Metastatic Breast Cancer Pretreated with Anthracyclines – A Phase II Multipractice Study
Researchers examined the efficacy and safety of weekly paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients. [BMC Cancer] Full Article

Phase II Study of Irinotecan Plus Capecitabine in Anthracycline- and Taxane- Pretreated Patients with Metastatic Breast Cancer
To evaluate the efficacy and tolerability of combined treatment with irinotecan (I) and capecitabine (X), researchers conducted a phase II study of the IX combination in anthracycline- and taxane-pretreated patients with metastatic breast cancer. [Invest New Drugs] Abstract

Penn Receives $25 Million Gift to Create Basser Research Center for Inherited Cancers
A $25 million gift to the University of Pennsylvania (Penn) will establish a center focused on the treatment and prevention of cancers associated with hereditary BRCA mutations. [University of Pennsylvania]
Press Release

Celldex Announced Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer
Celldex Therapeutics, Inc. announced that interim, topline results of the Phase IIb EMERGE study of CDX-011 in patients with advanced breast cancer will be presented. [Celldex Therapeutics, Inc.] Press Release

Exelixis Expands the Cabozantinib Development Program through NCI-CTEP Collaboration
Exelixis, Inc. announced a broad expansion of the cabozantinib development program under a Cooperative Research and Development Agreement with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP), with the approval of the initial program of 12 proposed clinical trials under the agreement. [Exelixis, Inc.] Press Release

Generex Announces Establishment of a Scientific Advisory Board for Antigen Express
Generex Biotechnology Corporation announced that a Scientific Advisory Board (SAB) has been established for its wholly-owned oncology immuno-therapeutics subsidiary, Antigen Express, Inc. The initial focus of the SAB will be to review the Phase II clinical trial of the Antigen Express AE37 breast cancer vaccine and facilitate the transition into a Phase III clinical trial. [Generex Biotechnology Corporation] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 13^th St. Gallen-Breast Cancer Conference 2013
March 13-16, 2013
St. Galen, Switzerland

Visit our events page to see a complete list of events in the mammary cell community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Postdoctoral Position – Breast Cancer Biology (Bellvitge Institute for Biomedical Research)

Postdoc Positions – Molecular Cancer Biology (Baylor College of Medicine)

Postdoctoral Position – Breast Cancer Research (Beckman Research Institute)

Research Fellowship – Transformed Signal Transduction Networks in Breast Cancer (Memorial Sloan-Kettering Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.